Mochi Health vs PlushCare: Which GLP-1 Platform Is Right for You?

You have insurance and you’re weighing whether to use it, or you’re paying out of pocket and trying to find the least painful monthly bill. That single question — insured versus cash-pay — is the hinge on which this entire comparison turns.

Mochi Health and PlushCare represent two genuinely different philosophies about how GLP-1 care should work. One is a weight-management specialist built around cash-pay compounding. The other is a primary-care telehealth platform built around insurance-covered branded drugs. Neither is universally better. But for a given patient’s situation, one is usually clearly right.

TL;DR Verdict

Choose Mochi Health if: You are uninsured or your insurance excludes GLP-1s, you want compounded semaglutide or tirzepatide at flat-rate pricing, and you accept that Mochi’s compounding program carries litigation and regulatory risks that branded programs do not.

Choose PlushCare if: You have commercial insurance with GLP-1 coverage (or a realistic shot at PA approval), you want branded Wegovy, Ozempic, Zepbound, or Mounjaro, and you want a physician who will fight your insurer on peer-to-peer review.

At-a-Glance Comparison

Prices as of May 2026. Verify current pricing before enrolling.

The Models Are Fundamentally Different

Mochi Health launched as a weight-management specialist. Its clinical infrastructure — mandatory video consultation, same-provider continuity, monthly progress questionnaires, and a tiered pharmacy network — is built around one goal: getting patients on GLP-1s and keeping them there. The compounded program is the core product, with branded prescriptions available as a secondary offering for insured patients.

PlushCare is the opposite. It started as a primary-care telehealth platform and added weight management to its existing menu of urgent care, chronic disease management, and preventive services. When a PlushCare physician prescribes Wegovy, they are doing what primary-care physicians have always done: diagnosing a chronic condition, selecting an FDA-approved treatment, and working within the insurance system to fund it. Compounded GLP-1s are an afterthought — effectively off the menu since the FDA shortage declarations expired.

That structural difference shapes every downstream comparison.

Pricing: What You’ll Actually Pay

Cash-pay patients

Mochi’s pricing is genuinely transparent once you know where to look. The $39 figure in its advertising is a discounted membership rate that omits medication costs. The real floor is:

• Compounded semaglutide: $99/mo at any dose + $79/mo membership = $178/mo total
• Compounded tirzepatide: $199/mo at any dose + $79/mo membership = $278/mo total

Flat-rate pricing across all doses is a meaningful feature. On Mochi, escalating from 0.25 mg to 2.4 mg semaglutide costs the same per month. That removes the dose-escalation penalty that affects other cash-pay providers.

Reddit users who have been around the GLP-1 telehealth ecosystem long enough are cautious. One r/Semaglutide commenter summed it up: “Memberships are typically a red flag. They charge $79 membership fee a month and then $99 for meds.” That observation is directionally fair — Mochi costs more per month than providers without a membership structure — but Mochi’s consolidated clinical model (included visits, pharmacy coordination, provider messaging) makes a straight cost comparison incomplete.

PlushCare’s cash-pay math is punishing. The $19.99 membership buys platform access, not clinical care. Each video visit runs $129. NovoCare Wegovy is currently $349/mo (or $199/mo intro for the two lowest doses, as of May 2026). Add it up and an uninsured PlushCare patient can expect $500–$650+ monthly in year one. PlushCare is not designed for cash-pay patients seeking GLP-1s, and it does not pretend otherwise.

Insured patients

This is where PlushCare pulls ahead sharply. In-network with 100+ commercial plans including Aetna, Cigna, UnitedHealthcare, Anthem, and Humana, PlushCare patients with GLP-1 coverage often pay only their drug copay plus the $19.99 membership. A patient on employer insurance with $50 Wegovy copay and a PA approval might pay $70/mo all-in — less than half of Mochi’s compounded floor.

Mochi accepts insurance for branded prescriptions too, but insurance coverage is secondary to its compounding business. Patients who need aggressive PA advocacy consistently report better outcomes with providers — like PlushCare — built around that workflow from the start.

Drug Access: What Each Can Prescribe

Mochi Health prescribes:

• Compounded semaglutide (injection, oral tablet, oral drops, microdose) — cash-pay
• Compounded tirzepatide (injection) — cash-pay
• Ozempic, Wegovy, Mounjaro, Zepbound, Rybelsus, Saxenda — branded, insurance/PA

PlushCare prescribes:

• Wegovy, Ozempic, Zepbound, Mounjaro, Saxenda, Rybelsus, Contrave, Xenical — branded, insurance/PA
• Compounded semaglutide — only when FDA shortage list active (effectively unavailable post-February 2025)

One important caveat on Mochi’s oral compounded options: a vocal thread in r/Semaglutide flagged that compounded oral semaglutide is physiologically questionable. The native GLP-1 peptide does not survive gastric fluids without Novo Nordisk’s proprietary enteric coating — the same coating that makes Rybelsus viable. Compounded oral formulations lack this technology. Your prescriber determines what is clinically appropriate for your situation; this is a question worth raising before selecting an oral compounded option.

Prior Authorization Support

PA support is where PlushCare earns its strongest differentiation for insured patients.

PlushCare physicians can initiate peer-to-peer review calls directly with insurance medical directors when initial PA requests are denied. This matters. Insurance companies frequently auto-deny first PA attempts; peer-to-peer calls — where a physician argues clinical necessity to the insurer’s own doctor — have materially higher overturn rates than written appeals alone.

The limitation is consistency. A Reddit user in r/Ozempic, trying to get Zepbound covered on an Arizona state employer plan, described a PlushCare experience where “the doc seemed a bit passive.” Quality varies by individual physician. PlushCare’s platform is capable of aggressive PA advocacy; whether the specific doctor you’re assigned delivers it is less certain.

Mochi offers PA support for branded prescriptions, but the workflow is designed around the compounded program. Patients seeking aggressive insurer navigation are generally better served by a primary-care-native platform.

Compounding: Mochi’s Advantage and Its Risk

The compounding option is Mochi’s clearest differentiator. For patients without functional insurance coverage for GLP-1s, it represents access to semaglutide and tirzepatide at prices roughly 65–75% below branded list prices.

The legal and regulatory context is essential to understand before enrolling.

Why compounding is still legal (barely): The FDA removed semaglutide from the drug shortage list on February 21, 2025. It removed tirzepatide on October 2, 2024. Under the compounding law framework, shortage status was the primary federal justification for 503B outsourcing facilities. The last enforcement-discretion windows for both drugs expired May 22, 2025. What remains is the §503A pathway — individual patient prescriptions filled by traditional 503A compounding pharmacies — which Mochi uses. This pathway is legally distinct from the now-expired 503B bulk-compounding window and is not currently subject to an FDA enforcement action. Your prescriber determines whether a §503A prescription is appropriate for your specific clinical situation.

The Aequita shutdown: Aequita Pharmacy, a Mochi compounding partner, was shut down by Washington state regulators in March 2025. Regulators cited deficient sterile compounding practices including untrained staff and failure to adhere to USP protocols. Mochi has since expanded its pharmacy network beyond Aequita. The shutdown does not affect current dispensing, but it underlines that compounding pharmacy quality varies and that the network Mochi routes patients through matters.

The Eli Lilly lawsuit: Eli Lilly filed a federal suit against Mochi Health in July 2025, alleging unfair competition under California law and trademark infringement under the Lanham Act. Lilly’s central claim is that Mochi used Lilly’s brand names, clinical trial data, and product imagery to imply its compounded tirzepatide had been studied in the same trials as Mounjaro. As of early 2026, the case has survived Mochi’s second motion to dismiss and is proceeding. A ruling for Lilly could restrict Mochi’s compounding operations. A ruling for Mochi would confirm that its current model is legally defensible. The outcome is genuinely uncertain.

This is not a reason to avoid Mochi automatically, but it is material information for any patient whose treatment continuity depends on the compounded program persisting.

Clinical Model: Specialist vs. Generalist

Mochi’s model centers weight loss. Every physician on the platform sees primarily weight management cases. Mandatory video consultations, six-month follow-up visits, and monthly progress questionnaires create a structured longitudinal program. Patients can message their provider between visits and access the same physician consistently. The tradeoff is that Mochi cannot manage other chronic conditions — it is not a primary care replacement.

PlushCare’s model is primary care with GLP-1 capability. A PlushCare physician managing your weight loss can also handle your hypertension, your UTI, and your annual bloodwork in the same platform. Same-day appointments are routinely available within 30 minutes. For patients who want their weight management to live inside a broader clinical relationship, that continuity has value. The tradeoff is that weight management is not the platform’s only or primary product — physician depth on GLP-1 dosing and pharmacology varies.

Who Chooses Mochi Health

• No insurance coverage for GLP-1s and unwilling to pay branded list prices
• Wants access to compounded tirzepatide (tirzepatide remains off most insurance formularies for weight loss without a diabetes diagnosis)
• Comfortable with the §503A legal framework and the Lilly litigation risk
• Prefers flat-rate pricing across all dose escalations
• Does not need a single platform to handle other health conditions

Who Chooses PlushCare

• Has commercial insurance with GLP-1 coverage or a realistic PA approval path
• Wants FDA-approved branded medications (Wegovy, Zepbound, Ozempic, Mounjaro)
• Values peer-to-peer PA advocacy when insurers deny first
• Wants weight management inside a broader primary-care relationship
• Can tolerate the $19.99/mo membership and per-visit fees as part of an insurance-subsidised total

Risk Factors Side by Side

Mochi Health risks:

• Eli Lilly unfair-competition lawsuit ongoing (could restrict compounding access)
• Aequita Pharmacy shutdown (March 2025) raised pharmacy quality questions
• Misleading advertising: the $39 entry price omits the full cost structure
• §503A compounding pathway could face additional regulatory scrutiny
• Oral compounded GLP-1 efficacy questions (bioavailability without enteric coating)

PlushCare risks:

• Robbins v. PlushCare Inc. class action settled October 2023 (deceptive auto-renewal enrollment)
• Billing and auto-renewal complaints remain the dominant Trustpilot negative theme
• PA outcome quality varies by physician — no guaranteed aggressive advocacy
• Effectively no compounded option available since semaglutide shortage resolution
• BBB rating 2.09/5 (primarily billing-related)

FAQ

Is Mochi Health or PlushCare cheaper? For cash-pay patients, Mochi is cheaper: compounded semaglutide costs $99/mo plus a $79/mo membership, totalling $178/mo. PlushCare’s cash-pay path runs roughly $500–$650/mo (membership + visit fees + branded drug). For insured patients, PlushCare is often far cheaper — copays cover visits and brand-name GLP-1 costs can drop significantly with PA approval.

Does PlushCare prescribe compounded semaglutide? Rarely, and effectively no longer. PlushCare’s policy restricts compounding to periods when brand-name drugs appear on the FDA shortage list. Semaglutide was removed from the shortage list on February 21, 2025. PlushCare’s clinical model is built around FDA-approved branded medications.

Does Mochi Health accept insurance? For brand-name medications only. Mochi accepts insurance for Wegovy, Ozempic, Mounjaro, and Zepbound, and offers PA support for those prescriptions. Its compounded GLP-1 program — the one most patients enrol for — is cash-pay only.

What happened to Aequita Pharmacy? Aequita, a key Mochi compounding partner, was shut down by Washington state regulators in March 2025 for unsafe sterile compounding practices, including untrained staff and failure to follow USP standards. Mochi subsequently expanded its pharmacy network. Eli Lilly named Aequita in its ongoing lawsuit against Mochi Health.

Can PlushCare help with prior authorization denials? Yes. PlushCare physicians can initiate peer-to-peer calls with insurance medical directors to appeal PA denials — a capability most telehealth competitors do not offer. PA timelines typically run 7–14 days on initial submission.

Is Mochi Health’s flat-rate pricing real? Mostly. Compounded semaglutide is $99/mo at any dose, and compounded tirzepatide is $199/mo at any dose — confirmed by multiple independent reviews as of May 2026. The catch is the mandatory $79/mo membership, which makes the true floor $178/mo for semaglutide and $278/mo for tirzepatide.

What is the Eli Lilly lawsuit against Mochi Health about? Eli Lilly filed suit in July 2025 alleging Mochi misled patients by using Lilly brand names, clinical trial data (SURMOUNT, SURPASS), and product imagery to promote compounded tirzepatide. As of early 2026, the case has survived Mochi’s second motion to dismiss and is proceeding in federal court in San Francisco under the Lanham Act and California’s Unfair Competition Law.

Who is PlushCare’s parent company? PlushCare is owned by Accolade, Inc. (NASDAQ: ACCD), a health navigation and advocacy company that acquired PlushCare in 2021 for approximately $450 million. This corporate backing underpins its in-network status with 100+ commercial insurance plans.

Metabolic Ledger is an editorial publication. We have no financial relationship with Mochi Health or PlushCare. All pricing figures are independently verified from public sources and dated May 2026 — verify current rates before enrolling. This page does not constitute medical advice; your prescriber determines what treatment is appropriate for your situation. See our full provider comparison, or read our individual Mochi Health review and PlushCare review. For cash-pay cost options across multiple providers, see cheapest place to get Wegovy.